Kazia Therapeutics expands Paxalisib trial into HR+/HER2- breast cancer
Kazia Therapeutics is expanding the Paxalisib clinical trial into HR+/HER2- breast cancer, citing preclinical data supporting strong clinical activity and safety. The three-arm expansion adds Paxalisib plus fulvestrant versus standard of care, with first patient expected soon.
Preclinical Data Show Paxalisib Combined With Standard-of-Care Therapy Is Well Tolerated and Produces Statistically Significant Antitumor ActivityThree-Arm Expansion of the Ongoing TNBC Trial Will Evaluate Paxalisib Plus Fulvestrant, With Palbociclib, Versus Standard-of-CareFirst Patient Expected B…